Cipla signs exclusive licensing deal with SBP Group for HER2-targeted ADC
SBP Group subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ) has granted Cipla exclusive rights to develop and commercialise TQB2102 in India, South Africa and five other emerging markets
Cipla and Sino Biopharmaceutical (SBP Group) recently announced an exclusive license and supply agreement for Rolditamig Deuderuxtecan, also known as TQB2102, a potential best-in-class HER2 bispecific antibody-drug conjugate (ADC).
Under the agreement, SBP Group subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ) has granted Cipla exclusive rights to develop and commercialise TQB2102 in India, South Africa and five other emerging markets.
Cipla will be responsible for local clinical development, regulatory activities and commercialisation in the licensed territories, while CTTQ will continue to manufacture and supply TQB2102.
TQB2102 is being evaluated across HER2-expressing cancers and has demonstrated encouraging clinical potential in HER2-low advanced breast cancer.
The collaboration brings together SBP Group’s late-stage oncology asset and development and manufacturing capabilities with Cipla’s established regulatory, medical, market access and commercial presence across India, South Africa and other emerging markets.
The companies said the partnership is intended to accelerate local development and regulatory approvals and enable patient access across the licensed countries, subject to applicable approvals.